多剤耐性結核治療薬市場：薬剤クラス別、治療タイプ別、治療アプローチ別、剤形別、治療レジメン期間別、エンドユーザー別、流通チャネル別-2025-2030年世界予測

多剤耐性結核治療薬市場は、2024年には3億6,875万米ドルとなり、2025年には4億901万米ドル、CAGR11.19%で成長し、2030年には6億9,720万米ドルに達すると予測されています。

多剤耐性結核（MDR-TB）は、革新的で適応性のある治療戦略を必要とする、世界的に手ごわい公衆衛生上の課題を提起し続けています。最近の薬剤開発と治療レジメンの動向は、従来の画一的なモデルからより的を絞ったアプローチに取って代わられる新時代の到来を告げています。本レポートは、MDR-TB治療薬の現状を包括的に分析し、科学的ブレークスルーと、進化する経済・規制・臨床状況の両方を捉えています。新たな薬物療法、製剤の改良、進化する治療プロトコルの間のダイナミックな相互作用を検証しています。急速に変化する進歩を特徴とし、患者の転帰を改善する必要性が絶えないこの分野では、市場の細分化、技術革新、地域格差の複雑な詳細を理解することが重要です。本書は、臨床試験、薬剤の有効性、患者アクセスに関する懸念のギャップを埋めながら、多面的な調査を掘り下げています。ここで提供される洞察は、意思決定者や業界専門家に実用的な情報を提供し、現在の治療課題に対処するだけでなく、MDR-TB管理における将来の動向を予測する戦略の基礎を築くことを目的としています。

多剤耐性結核治療薬市場の変革

過去数年間、MDR-TBの治療状況は、科学的革新と規制の再調整の両方により、画期的な変化を遂げてきました。新規作用機序と改良型製剤を融合させ、有効性のギャップを効果的に埋め、治療期間を短縮する併用治療へのシフトが顕著になっています。規制機関は、承認プロセスを合理化することで効果的な医薬品に対する緊急のニーズに対応し、救命薬への迅速なアクセスを促進しています。研究開発への投資は発見のペースを加速させ、分子診断学や個別化医療アプローチを治療デザインに活用する進歩を推進しました。こうした進歩と並行して、患者のコンプライアンスと治療成果をモニターするデジタルヘルス技術の統合がますます重視されるようになっています。このような変革的なシフトは、臨床診療を再定義するだけでなく、研究者、製薬企業、規制当局間のより協力的なエコシステムを促進しました。市場の層別要素を検討すると、適応性、革新性、規制当局の先見性が、MDR-TB治療薬の進化を推進する要であることが明らかになります。

市場セグメンテーションの重要な洞察が市場のニュアンスを明らかにする

市場セグメンテーションを深く掘り下げることで、MDR-TB治療薬市場の構造と進化を支える重要な洞察が明らかになります。薬剤クラス別では、ベダキリン、イソニアジド、レボフロキサシン、リネゾリド、リファンピンといった薬剤が治療選択肢として挙げられ、各薬剤が耐性メカニズムとの戦いにおいて明確な役割を果たしています。同様に重要なのは、治療の種類に基づく分析であり、薬物療法に基づく治療と薬物療法以外の治療の両方を評価し、補助療法がどのように一次治療レジメンを補完し、強化するかを示しています。治療アプローチは、併用療法と単剤療法に分けられ、効果を最適化する多剤併用レジメンへの戦略的シフトが明らかにされています。さらに、市場は薬剤の剤形によって区分され、患者のアドヒアランスと治療成績に影響を与える重要なデリバリー形式は、カプセル、注射剤、錠剤です。治療レジメンの期間も重要な要素で、長期投与レジメンと短期投与レジメンを対比し、それぞれに課題と利点があります。また、病院、オンライン薬局、小売薬局、専門クリニックにまたがるエンドユーザーや、病院薬局、オンライン薬局、小売薬局で提供される製品を区別する流通チャネルにも注目しています。これらのセグメンテーション分析により、MDR-TB治療薬市場を形成する多様な要素に関する微妙な洞察が得られます。

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界的に薬剤耐性結核の蔓延が増加
    • 消費者の間で早期発見と個別化医療に対する意識が高まっている
    • 世界的に新薬開発のための研究開発活動が増加
  • 抑制要因
    • 多剤耐性結核治療薬に関連する高コスト
  • 機会
    • 結核治療の管理にデジタルヘルスケアソリューションを統合するための支援イニシアチブ
    • MDR-TBの患者転帰を改善し、治療期間を短縮するための併用療法の開発
  • 課題
    • 多剤耐性結核の治療に伴う複雑さ
• 市場セグメンテーション分析
  • 治療の種類：生活の質を高める役割を果たすため、非薬物療法が好まれる傾向が高まっている
  • エンドユーザー：病院におけるMDR-TB治療薬の重要性の高まり
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社会
  • 技術的
  • 法律上
  • 環境

第6章 多剤耐性結核治療薬市場薬剤クラス別

• ベダキリン
• イソニアジド
• レボフロキサシン
• リネゾリド
• リファンピシン

第7章 多剤耐性結核治療薬市場治療の種類別

• 薬物療法
• 非薬物療法

第8章 多剤耐性結核治療薬市場治療アプローチ別

• 併用療法
• 単剤療法

第9章 多剤耐性結核治療薬市場薬剤処方別

• カプセル
• 注射剤
• タブレット

第10章 多剤耐性結核治療薬市場治療レジメン期間別

• 長期治療レジメン
• 短期コースレジメン

第11章 多剤耐性結核治療薬市場：エンドユーザー別

• 病院
• オンライン薬局
• 小売薬局
• 専門クリニック

第12章 多剤耐性結核治療薬市場：流通チャネル別

• 病院薬局
• オンライン薬局
• 小売薬局

第13章 南北アメリカの多剤耐性結核治療薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第14章 アジア太平洋地域の多剤耐性結核治療薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第15章 欧州・中東・アフリカの多剤耐性結核治療薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第16章 競合情勢

• 市場シェア分析, 2024
• FPNVポジショニングマトリックス, 2024
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Abbott Laboratories
• Abcam Limited
• AstraZeneca
• Aurobindo Pharma Ltd.
• Cipla Inc.
• Daiichi Sankyo Co., Ltd.
• Eli Lilly and Company
• Endo International Plc
• F. Hoffmann-La Roche Ltd
• GlaxoSmithKline plc
• Johnson & Johnson Services Inc.
• Lupin Limited
• Macleods Pharmaceuticals Ltd.
• Merck & Co., Inc.
• Mylan N.V.
• Novartis AG
• Otsuka Pharmaceutical Co., Ltd.
• Oxford Immunotec
• Pfizer Inc.
• QureTech Bio AB
• Sanofi SA
• Santen Pharmaceutical Co., Ltd.
• Sequella, Inc.
• Shanghai Fosun Pharmaceutical（Group）Co., Ltd.

LIST OF FIGURES

• FIGURE 1. MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET MULTI-CURRENCY
• FIGURE 2. MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET MULTI-LANGUAGE
• FIGURE 3. MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET RESEARCH PROCESS
• FIGURE 4. MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, 2024 VS 2030
• FIGURE 5. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 6. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 7. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
• FIGURE 9. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
• FIGURE 11. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2024 VS 2030 (%)
• FIGURE 13. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2024 VS 2030 (%)
• FIGURE 15. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 16. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2024 VS 2030 (%)
• FIGURE 17. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 18. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
• FIGURE 19. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 20. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
• FIGURE 21. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 22. AMERICAS MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 23. AMERICAS MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 24. UNITED STATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
• FIGURE 25. UNITED STATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 26. ASIA-PACIFIC MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 27. ASIA-PACIFIC MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 28. EUROPE, MIDDLE EAST & AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 29. EUROPE, MIDDLE EAST & AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 30. MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 31. MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET DYNAMICS
• TABLE 7. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY BEDAQUILINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ISONIAZID, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY LEVOFLOXACIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY LINEZOLID, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY RIFAMPIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION-BASED TREATMENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY NON-MEDICATION THERAPIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY COMBINATION TREATMENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY INJECTABLES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TABLETS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY LONG-COURSE REGIMENS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY SHORT-COURSE REGIMENS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 33. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 34. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 35. AMERICAS MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 36. AMERICAS MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 37. AMERICAS MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
• TABLE 38. AMERICAS MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
• TABLE 39. AMERICAS MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2018-2030 (USD MILLION)
• TABLE 40. AMERICAS MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 41. AMERICAS MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 42. AMERICAS MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 43. ARGENTINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 44. ARGENTINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 45. ARGENTINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
• TABLE 46. ARGENTINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
• TABLE 47. ARGENTINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2018-2030 (USD MILLION)
• TABLE 48. ARGENTINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 49. ARGENTINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 50. BRAZIL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 51. BRAZIL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 52. BRAZIL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
• TABLE 53. BRAZIL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
• TABLE 54. BRAZIL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2018-2030 (USD MILLION)
• TABLE 55. BRAZIL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 56. BRAZIL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 57. CANADA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 58. CANADA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 59. CANADA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
• TABLE 60. CANADA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
• TABLE 61. CANADA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2018-2030 (USD MILLION)
• TABLE 62. CANADA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 63. CANADA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 64. MEXICO MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 65. MEXICO MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 66. MEXICO MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
• TABLE 67. MEXICO MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
• TABLE 68. MEXICO MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2018-2030 (USD MILLION)
• TABLE 69. MEXICO MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 70. MEXICO MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 71. UNITED STATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 72. UNITED STATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 73. UNITED STATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
• TABLE 74. UNITED STATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
• TABLE 75. UNITED STATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2018-2030 (USD MILLION)
• TABLE 76. UNITED STATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 77. UNITED STATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 78. UNITED STATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 79. ASIA-PACIFIC MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 80. ASIA-PACIFIC MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 81. ASIA-PACIFIC MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
• TABLE 82. ASIA-PACIFIC MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
• TABLE 83. ASIA-PACIFIC MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2018-2030 (USD MILLION)
• TABLE 84. ASIA-PACIFIC MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 85. ASIA-PACIFIC MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 86. ASIA-PACIFIC MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 87. AUSTRALIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 88. AUSTRALIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 89. AUSTRALIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
• TABLE 90. AUSTRALIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
• TABLE 91. AUSTRALIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2018-2030 (USD MILLION)
• TABLE 92. AUSTRALIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 93. AUSTRALIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 94. CHINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 95. CHINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 96. CHINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
• TABLE 97. CHINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
• TABLE 98. CHINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2018-2030 (USD MILLION)
• TABLE 99. CHINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 100. CHINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 101. INDIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 102. INDIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 103. INDIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
• TABLE 104. INDIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
• TABLE 105. INDIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2018-2030 (USD MILLION)
• TABLE 106. INDIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 107. INDIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 108. INDONESIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 109. INDONESIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 110. INDONESIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
• TABLE 111. INDONESIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
• TABLE 112. INDONESIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2018-2030 (USD MILLION)
• TABLE 113. INDONESIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 114. INDONESIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 115. JAPAN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 116. JAPAN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 117. JAPAN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
• TABLE 118. JAPAN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
• TABLE 119. JAPAN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2018-2030 (USD MILLION)
• TABLE 120. JAPAN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 121. JAPAN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 122. MALAYSIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 123. MALAYSIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 124. MALAYSIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
• TABLE 125. MALAYSIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
• TABLE 126. MALAYSIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2018-2030 (USD MILLION)
• TABLE 127. MALAYSIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 128. MALAYSIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 129. PHILIPPINES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 130. PHILIPPINES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 131. PHILIPPINES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
• TABLE 132. PHILIPPINES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
• TABLE 133. PHILIPPINES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2018-2030 (USD MILLION)
• TABLE 134. PHILIPPINES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 135. PHILIPPINES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 136. SINGAPORE MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 137. SINGAPORE MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 138. SINGAPORE MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
• TABLE 139. SINGAPORE MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
• TABLE 140. SINGAPORE MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2018-2030 (USD MILLION)
• TABLE 141. SINGAPORE MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 142. SINGAPORE MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 143. SOUTH KOREA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 144. SOUTH KOREA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 145. SOUTH KOREA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
• TABLE 146. SOUTH KOREA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
• TABLE 147. SOUTH KOREA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2018-2030 (USD MILLION)
• TABLE 148. SOUTH KOREA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 149. SOUTH KOREA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 150. TAIWAN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 151. TAIWAN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 152. TAIWAN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
• TABLE 153. TAIWAN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
• TABLE 154. TAIWAN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2018-2030 (USD MILLION)
• TABLE 155. TAIWAN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 156. TAIWAN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 157. THAILAND MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 158. THAILAND MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 159. THAILAND MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
• TABLE 160. THAILAND MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
• TABLE 161. THAILAND MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2018-2030 (USD MILLION)
• TABLE 162. THAILAND MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 163. THAILAND MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 164. VIETNAM MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 165. VIETNAM MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 166. VIETNAM MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
• TABLE 167. VIETNAM MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
• TABLE 168. VIETNAM MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2018-2030 (USD MILLION)
• TABLE 169. VIETNAM MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 170. VIETNAM MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 171. EUROPE, MIDDLE EAST & AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 172. EUROPE, MIDDLE EAST & AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 173. EUROPE, MIDDLE EAST & AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
• TABLE 174. EUROPE, MIDDLE EAST & AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
• TABLE 175. EUROPE, MIDDLE EAST & AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2018-2030 (USD MILLION)
• TABLE 176. EUROPE, MIDDLE EAST & AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 177. EUROPE, MIDDLE EAST & AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 178. EUROPE, MIDDLE EAST & AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 179. DENMARK MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 180. DENMARK MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 181. DENMARK MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
• TABLE 182. DENMARK MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
• TABLE 183. DENMARK MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2018-2030 (USD MILLION)
• TABLE 184. DENMARK MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 185. DENMARK MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 186. EGYPT MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 187. EGYPT MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 188. EGYPT MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
• TABLE 189. EGYPT MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
• TABLE 190. EGYPT MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2018-2030 (USD MILLION)
• TABLE 191. EGYPT MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 192. EGYPT MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 193. FINLAND MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 194. FINLAND MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 195. FINLAND MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
• TABLE 196. FINLAND MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
• TABLE 197. FINLAND MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2018-2030 (USD MILLION)
• TABLE 198. FINLAND MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 199. FINLAND MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 200. FRANCE MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 201. FRANCE MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 202. FRANCE MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
• TABLE 203. FRANCE MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
• TABLE 204. FRANCE MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2018-2030 (USD MILLION)
• TABLE 205. FRANCE MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 206. FRANCE MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 207. GERMANY MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 208. GERMANY MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 209. GERMANY MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
• TABLE 210. GERMANY MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
• TABLE 211. GERMANY MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2018-2030 (USD MILLION)
• TABLE 212. GERMANY MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 213. GERMANY MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 214. ISRAEL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 215. ISRAEL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 216. ISRAEL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
• TABLE 217. ISRAEL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
• TABLE 218. ISRAEL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2018-2030 (USD MILLION)
• TABLE 219. ISRAEL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 220. ISRAEL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 221. ITALY MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 222. ITALY MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 223. ITALY MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
• TABLE 224. ITALY MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
• TABLE 225. ITALY MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2018-2030 (USD MILLION)
• TABLE 226. ITALY MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 227. ITALY MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 228. NETHERLANDS MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 229. NETHERLANDS MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 230. NETHERLANDS MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
• TABLE 231. NETHERLANDS MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
• TABLE 232. NETHERLANDS MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2018-2030 (USD MILLION)
• TABLE 233. NETHERLANDS MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 234. NETHERLANDS MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 235. NIGERIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 236. NIGERIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 237. NIGERIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
• TABLE 238. NIGERIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
• TABLE 239. NIGERIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2018-2030 (USD MILLION)
• TABLE 240. NIGERIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 241. NIGERIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 242. NORWAY MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 243. NORWAY MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 244. NORWAY MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
• TABLE 245. NORWAY MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
• TABLE 246. NORWAY MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2018-2030 (USD MILLION)
• TABLE 247. NORWAY MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 248. NORWAY MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 249. POLAND MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 250. POLAND MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 251. POLAND MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
• TABLE 252. POLAND MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
• TABLE 253. POLAND MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2018-2030 (USD MILLION)
• TABLE 254. POLAND MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 255. POLAND MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 256. QATAR MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 257. QATAR MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 258. QATAR MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
• TABLE 259. QATAR MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
• TABLE 260. QATAR MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2018-2030 (USD MILLION)
• TABLE 261. QATAR MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 262. QATAR MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 263. RUSSIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 264. RUSSIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 265. RUSSIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MI

The Multidrug-resistant Tuberculosis Therapeutics Market was valued at USD 368.75 million in 2024 and is projected to grow to USD 409.01 million in 2025, with a CAGR of 11.19%, reaching USD 697.20 million by 2030.

Multidrug-resistant tuberculosis (MDR-TB) continues to pose a formidable public health challenge globally, demanding innovative and adaptive therapeutic strategies. Recent advancements in drug development and treatment regimens have ushered in a new era where the traditional one-size-fits-all model is being replaced by more targeted approaches. This report provides a comprehensive analysis of the current state of MDR-TB therapeutics, capturing both the scientific breakthroughs and the evolving economic, regulatory, and clinical landscapes. It examines the dynamic interplay between emerging drug therapies, formulation improvements, and evolving treatment protocols. In a field characterized by rapidly changing advancements and a persistent need for improved patient outcomes, understanding the intricate details of market segmentation, technological innovation, and regional disparities is critical. This piece delves into the multifaceted research, bridging gaps between clinical trials, drug efficacy, and patient-access concerns. The insights offered herein are designed to empower decision-makers and industry professionals with actionable intelligence, laying the groundwork for strategies that not only address current therapeutic challenges, but also anticipate future trends in MDR-TB management.

Transformative Shifts in the MDR-TB Therapeutics Landscape

Over the past few years, the therapeutic landscape for MDR-TB has experienced groundbreaking transformations, driven by both scientific innovation and regulatory recalibration. There has been a pronounced shift towards combination treatments that merge novel mechanisms of action with enhanced drug formulations, effectively bridging gaps in efficacy and reducing treatment durations. Regulatory bodies have adapted to the urgent need for effective drugs by streamlining approval processes, facilitating faster access to life-saving medications. Investment in research and development has accelerated the pace of discovery, propelling advancements that leverage molecular diagnostics and personalized medicine approaches in treatment design. Parallel to these advancements, there has been an increasing emphasis on integrating digital health technologies that monitor patient compliance and treatment outcomes. These transformative shifts have not only redefined clinical practice but have also fostered a more collaborative ecosystem among researchers, pharmaceutical companies, and regulatory authorities. As we examine the stratified elements of the market, it becomes clear that adaptability, innovation, and regulatory foresight are the keystones driving this evolution in MDR-TB therapeutics.

Key Segmentation Insights Uncovering Market Nuances

A deep dive into market segmentation reveals critical insights that underpin the structure and evolution of the MDR-TB therapeutic landscape. The market is extensively studied based on drug class where therapeutic options include agents such as Bedaquiline, Isoniazid, Levofloxacin, Linezolid, and Rifampin, each playing a distinct role in combating resistance mechanisms. Equally important is the analysis based on treatment type which assesses both medication-based treatments as well as non-medication therapies, showcasing how adjunct therapies complement and enhance primary treatment regimens. The therapeutic approach is dissected into combination treatments and monotherapy modalities, revealing strategic shifts towards multi-drug regimens that optimize efficacy. Further, the market is segmented by drug formulation, with capsules, injectables, and tablets being the critical delivery formats that impact patient adherence and therapeutic outcomes. Duration of treatment regimens is another key dimension, contrasting long-course regimens with short-course alternatives, each with its own set of challenges and benefits. Attention is also given to the end user, which spans across hospitals, online pharmacies, retail pharmacies, and specialty clinics, as well as to the distribution channel that differentiates offerings made available through hospital pharmacies, online pharmacies, and retail pharmacies. Together, these segmentation analyses provide nuanced insights into the diverse components that shape the MDR-TB therapeutic market.

Based on Drug Class, market is studied across Bedaquiline, Isoniazid, Levofloxacin, Linezolid, and Rifampin.

Based on Treatment Type, market is studied across Medication-Based Treatments and Non-Medication Therapies.

Based on Therapeutic Approach, market is studied across Combination Treatments and Monotherapy.

Based on Drug Formulation, market is studied across Capsules, Injectables, and Tablets.

Based on Treatment Regimen Duration, market is studied across Long-Course Regimens and Short-Course Regimens.

Based on End User, market is studied across Hospitals, Online Pharmacies, Retail Pharmacies, and Specialty Clinics.

Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.

Regional Insights Illuminating Global Therapeutic Trends

The global perspective on MDR-TB therapeutics reveals significant regional variations that are critical for strategic planning. In the Americas, a mature healthcare infrastructure supports the rapid integration of novel therapies, and evolving policy frameworks ensure a robust pipeline for drug approval and market entry. The region comprising Europe, the Middle East, and Africa displays a blend of advanced research capabilities paired with emerging markets where regulatory reforms foster innovation and address unique patient-access challenges. Meanwhile, the Asia-Pacific region stands out for its dynamic market growth, supported by extensive research initiatives and high-volume clinical cases that drive the rapid deployment of new treatments. Variations in disease burden, government funding, and healthcare infrastructure mean that each region adapts differently to the influx of new therapeutic options. This region-specific analysis not only highlights differential market dynamics but also underscores the importance of tailoring strategies to meet localized needs, ensuring that global progress translates into accessible and effective treatments for all populations.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Company Insights Shaping the Future of MDR-TB Treatments

The competitive landscape in MDR-TB therapeutics is actively being reshaped by key industry players whose research and development efforts are paving the way for breakthrough therapies. Leading pharmaceutical companies such as Abbott Laboratories, Abcam Limited, AstraZeneca, and Aurobindo Pharma Ltd. have established themselves as innovators with robust pipelines and strategic partnerships. Industry giants like Cipla Inc., Daiichi Sankyo Co., Ltd., Eli Lilly and Company, and Endo International Plc are committed to bridging clinical gaps through advanced drug formulations and novel treatment modalities. Major players including F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Johnson & Johnson Services Inc., and Lupin Limited are known for their expansive market reach and significant contributions to clinical research. Other prominent organizations such as Macleods Pharmaceuticals Ltd., Merck & Co., Inc., Mylan N.V., Novartis AG, and Otsuka Pharmaceutical Co., Ltd. continue to drive the standard of care through rigorous testing and innovative clinical approaches. In addition, Oxford Immunotec, Pfizer Inc., QureTech Bio AB, Sanofi SA, Santen Pharmaceutical Co., Ltd., Sequella, Inc., and Shanghai Fosun Pharmaceutical (Group) Co., Ltd. further anchor the industry with diversified portfolios and forward-thinking strategies. These companies, each with distinct competencies and market strategies, collectively contribute to the evolution and accessibility of advanced MDR-TB treatments.

The report delves into recent significant developments in the Multidrug-resistant Tuberculosis Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Abcam Limited, AstraZeneca, Aurobindo Pharma Ltd., Cipla Inc., Daiichi Sankyo Co., Ltd., Eli Lilly and Company, Endo International Plc, F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Johnson & Johnson Services Inc., Lupin Limited, Macleods Pharmaceuticals Ltd., Merck & Co., Inc., Mylan N.V., Novartis AG, Otsuka Pharmaceutical Co., Ltd., Oxford Immunotec, Pfizer Inc., QureTech Bio AB, Sanofi SA, Santen Pharmaceutical Co., Ltd., Sequella, Inc., and Shanghai Fosun Pharmaceutical (Group) Co., Ltd.. Actionable Recommendations for Industry Leaders in MDR-TB Therapeutics

For industry leaders seeking to remain competitive in the rapidly evolving MDR-TB therapeutics landscape, a number of actionable strategies can be implemented. Leaders are encouraged to invest robustly in research and development, particularly in areas focusing on combination therapies and optimized drug formulations that cater to diverse patient populations. Strategic partnerships between pharmaceutical companies, public health agencies, and research institutions are essential to foster innovation and streamline the drug development process. It is pivotal to adopt agile regulatory strategies that accommodate emerging data and support faster market entry without compromising safety or efficacy. Embracing digital transformation through advanced monitoring and data analytics can enhance patient adherence and facilitate real-time decision-making, thereby improving overall treatment outcomes. Additionally, efforts must be channeled toward a comprehensive understanding of regional market dynamics, ensuring that strategies are tailored to meet specific regulatory standards and patient needs across different geographies. By aligning clinical research with market demand and maintaining a proactive stance towards collaboration, industry stakeholders can accelerate progress towards more effective MDR-TB treatment paradigms.

Conclusion: Navigating the Future of MDR-TB Therapeutics

In summary, the MDR-TB therapeutic market is at a critical juncture where scientific innovation, regulatory evolution, and strategic market segmentation converge to redefine treatment landscapes. The transformative shifts highlighted throughout this analysis underscore the importance of adopting combination therapies, innovative drug formulations, and patient-centric approaches. Bridging the gap between cutting-edge research and clinical applications is paramount in ensuring that treatments are not only effective, but also accessible to diverse populations across the globe. The integration of nuanced segmentation insights and regional perspectives provides a solid foundation for decision-makers, guiding them through the complexities of the current market environment. As industry leaders align their strategies with these multifaceted insights, they are better positioned to drive advancements in MDR-TB management, ultimately contributing to the global effort to curb the spread of drug-resistant tuberculosis.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising prevalence of drug-resistant tuberculosis globally
    • 5.1.1.2. Growing awareness about early detection and personalized medicine among consumers
    • 5.1.1.3. Increasing research & development activities for new drug development globally
  • 5.1.2. Restraints
    • 5.1.2.1. High costs associated with multidrug resistant tuberculosis therapeutics
  • 5.1.3. Opportunities
    • 5.1.3.1. Supportive initiatives for integrating digital healthcare solutions in managing tuberculosis treatments
    • 5.1.3.2. Development of combination therapies to improve patient outcomes and reduce treatment duration for MDR-TB
  • 5.1.4. Challenges
    • 5.1.4.1. Complexities associated with the treatment of multidrug-resistant tuberculosis
• 5.2. Market Segmentation Analysis
  • 5.2.1. Treatment Type: Rising preference for non-medication therapies owing to their role in enhancing quality of life
  • 5.2.2. End user: Increasing significance of MDR-TB therapeutics among hospitals
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Multidrug-resistant Tuberculosis Therapeutics Market, by Drug Class

• 6.1. Introduction
• 6.2. Bedaquiline
• 6.3. Isoniazid
• 6.4. Levofloxacin
• 6.5. Linezolid
• 6.6. Rifampin

7. Multidrug-resistant Tuberculosis Therapeutics Market, by Treatment Type

• 7.1. Introduction
• 7.2. Medication-Based Treatments
• 7.3. Non-Medication Therapies

8. Multidrug-resistant Tuberculosis Therapeutics Market, by Therapeutic Approach

• 8.1. Introduction
• 8.2. Combination Treatments
• 8.3. Monotherapy

9. Multidrug-resistant Tuberculosis Therapeutics Market, by Drug Formulation

• 9.1. Introduction
• 9.2. Capsules
• 9.3. Injectables
• 9.4. Tablets

10. Multidrug-resistant Tuberculosis Therapeutics Market, by Treatment Regimen Duration

• 10.1. Introduction
• 10.2. Long-Course Regimens
• 10.3. Short-Course Regimens

11. Multidrug-resistant Tuberculosis Therapeutics Market, by End User

• 11.1. Introduction
• 11.2. Hospitals
• 11.3. Online Pharmacies
• 11.4. Retail Pharmacies
• 11.5. Specialty Clinics

12. Multidrug-resistant Tuberculosis Therapeutics Market, by Distribution Channel

• 12.1. Introduction
• 12.2. Hospital Pharmacies
• 12.3. Online Pharmacies
• 12.4. Retail Pharmacies

13. Americas Multidrug-resistant Tuberculosis Therapeutics Market

• 13.1. Introduction
• 13.2. Argentina
• 13.3. Brazil
• 13.4. Canada
• 13.5. Mexico
• 13.6. United States

14. Asia-Pacific Multidrug-resistant Tuberculosis Therapeutics Market

• 14.1. Introduction
• 14.2. Australia
• 14.3. China
• 14.4. India
• 14.5. Indonesia
• 14.6. Japan
• 14.7. Malaysia
• 14.8. Philippines
• 14.9. Singapore
• 14.10. South Korea
• 14.11. Taiwan
• 14.12. Thailand
• 14.13. Vietnam

15. Europe, Middle East & Africa Multidrug-resistant Tuberculosis Therapeutics Market

• 15.1. Introduction
• 15.2. Denmark
• 15.3. Egypt
• 15.4. Finland
• 15.5. France
• 15.6. Germany
• 15.7. Israel
• 15.8. Italy
• 15.9. Netherlands
• 15.10. Nigeria
• 15.11. Norway
• 15.12. Poland
• 15.13. Qatar
• 15.14. Russia
• 15.15. Saudi Arabia
• 15.16. South Africa
• 15.17. Spain
• 15.18. Sweden
• 15.19. Switzerland
• 15.20. Turkey
• 15.21. United Arab Emirates
• 15.22. United Kingdom

16. Competitive Landscape

• 16.1. Market Share Analysis, 2024
• 16.2. FPNV Positioning Matrix, 2024
• 16.3. Competitive Scenario Analysis
  • 16.3.1. TB Alliance receives a USD 7.35 million fund from the U.S. Department of Defense's CDMRP to develop novel tuberculosis interventions
  • 16.3.2. The Indian Health Ministry's approval of the BPaLM regimen under the National TB Elimination Programme
  • 16.3.3. Johnson & Johnson receives a positive CHMP opinion recommending full EMA approval for SIRTURO
  • 16.3.4. Expanding Global Access to Groundbreaking DR-TB Treatment Through Strategic Partnerships
  • 16.3.5. Breakthrough in Global Fight Against MDR TB: Bedaquiline Patents Waived to Enhance Access in Low- and Middle-Income Countries
  • 16.3.6. Breakthrough in Combating Gram-Negative Bacterial Infections with Aztreonam-Avibactam's Clinical Triumphs
• 16.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. Abcam Limited
• 3. AstraZeneca
• 4. Aurobindo Pharma Ltd.
• 5. Cipla Inc.
• 6. Daiichi Sankyo Co., Ltd.
• 7. Eli Lilly and Company
• 8. Endo International Plc
• 9. F. Hoffmann-La Roche Ltd
• 10. GlaxoSmithKline plc
• 11. Johnson & Johnson Services Inc.
• 12. Lupin Limited
• 13. Macleods Pharmaceuticals Ltd.
• 14. Merck & Co., Inc.
• 15. Mylan N.V.
• 16. Novartis AG
• 17. Otsuka Pharmaceutical Co., Ltd.
• 18. Oxford Immunotec
• 19. Pfizer Inc.
• 20. QureTech Bio AB
• 21. Sanofi SA
• 22. Santen Pharmaceutical Co., Ltd.
• 23. Sequella, Inc.
• 24. Shanghai Fosun Pharmaceutical (Group) Co., Ltd.